Taylor Boyd

Chief Business Officer (CBO)

Taylor Boyd has more than a decade of experience in the life sciences industry, primarily focused on strategic transactions and capital raising activities across the biopharmaceutical ecosystem. Mr. Boyd joins Abzena from Longboard Pharmaceuticals where he served as Longboard’s Head of Business Development responsible for M&A, Transactions, and Partnerships prior to their $2.6Bn acquisition by Lundbeck in December of 2024.

Prior to joining Longboard, Mr. Boyd served as Vice President of Investor Relations at Oxford Biomedica plc (LSE: OXB), a pure-play cell and gene therapy focused CDMO. Prior to OXB, Mr. Boyd served as an investment banker covering the biopharmaceutical space for Raymond James, Leerink Partners, Cantor Fitzgerald and RBC Capital Markets where he completed more than $40 billion in mergers and acquisitions, debt and equity capital markets transactions. Prior to his career as an investment banker, Mr. Boyd was an Associate in Grant Thornton’s Transaction Advisory Services practice.

He holds a B.S. in Accounting from North Carolina State University an M.S. in Accounting from Wake Forest University.